Secondary Hyperparathyroidism

Secondary hyperparathyroidism (SHPT) is a compensatory, reactive elevation of parathyroid hormone (PTH) triggered by chronic hypocalcemia, vitamin D deficiency, or phosphate retention — as distinct from the autonomous, calcium-independent PTH excess of primary hyperparathyroidism. The most common cause worldwide is vitamin D deficiency, while chronic kidney disease (CKD) accounts for the majority of severe, clinically consequential SHPT encountered in nephrology practice. Understanding SHPT requires tracing the cascade from its root triggers through the mineral-hormone signaling network to the skeletal, vascular, and cardiac damage that accumulates when the condition goes uncontrolled.

Table of Contents

1. Overview
2. Mechanism in CKD
3. Other Causes
4. Tertiary Hyperparathyroidism
5. Clinical Presentation and Complications
6. Diagnosis and Laboratory Evaluation
7. Treatment
8. Prognosis and Monitoring
9. Key Research Papers
10. Connections
11. Featured Videos

Overview

Parathyroid hormone is the principal regulator of serum calcium. The four parathyroid glands — each roughly the size of a grain of rice, embedded on the posterior surface of the thyroid — continuously sense ionized calcium via the calcium-sensing receptor (CaSR). When ionized calcium falls, PTH secretion rises within seconds, mobilizing calcium from bone, increasing renal calcium reabsorption, and stimulating renal synthesis of active vitamin D (1,25-dihydroxyvitamin D3, calcitriol) to enhance intestinal calcium absorption. When calcium is restored, PTH secretion falls in a tight negative-feedback loop.

Primary hyperparathyroidism breaks this feedback: one or more parathyroid glands develop a single benign adenoma (85% of cases), hyperplasia (15%), or — rarely — carcinoma, and secrete PTH autonomously regardless of the calcium level. The result is hypercalcemia: PTH is high and calcium is high, because the gland is no longer listening to the CaSR signal telling it to stop.

Secondary hyperparathyroidism is the mirror image. The parathyroid glands are entirely intact and their feedback mechanisms are working — but the stimulus driving PTH upward is chronic and relentless. Serum calcium is low or low-normal (not elevated) because the underlying cause keeps pulling calcium down. PTH rises reactively, doing exactly what it is supposed to do: fighting to restore calcium. The parathyroid glands are not diseased in SHPT — they are responding normally to an abnormal environment. Over time, however, prolonged stimulation causes diffuse hyperplasia, and eventually nodular hyperplasia with some autonomous secretion, blurring into tertiary disease.

The two dominant causes of SHPT globally are quite different in severity:

• Vitamin D deficiency is the most common cause worldwide, affecting an estimated one billion people. Most cases are mild to moderate, treatable with oral supplementation, and reversible. It causes SHPT because vitamin D is required for intestinal calcium absorption; without adequate calcitriol, dietary calcium passes through the gut unabsorbed, serum calcium dips, and PTH rises to compensate.
• Chronic kidney disease (CKD) causes the most severe and clinically dangerous SHPT. As kidney function declines, a complex cascade of mineral dysregulation unfolds — involving phosphate, FGF-23, vitamin D, and PTH — that drives progressive parathyroid hyperplasia, renal osteodystrophy, vascular calcification, and cardiovascular mortality. This CKD-mineral and bone disorder (CKD-MBD) is the defining complication of advanced renal failure.

Back to Table of Contents

Mechanism in CKD

The development of SHPT in CKD is not a single event but a cascading sequence of mineral-hormone disturbances that begins early — often at GFR stages G3a-G3b (45-30 mL/min/1.73 m²) — and accelerates as kidney function deteriorates toward end-stage renal disease (ESRD). The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 guidelines define CKD-MBD as the systemic disorder of mineral and bone metabolism that occurs as a complication of CKD, manifested by one or more of the following: laboratory abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism; bone abnormalities; or vascular or soft tissue calcification.

Step-by-Step CKD-MBD Cascade

Step 1 — Phosphate retention begins early. The kidney is the primary route of phosphate excretion. As GFR falls, each remaining nephron must excrete proportionally more phosphate. Early in CKD, this is accomplished by rising PTH and FGF-23, which both inhibit tubular phosphate reabsorption. Serum phosphate remains near-normal until GFR is very low, but the price paid is escalating PTH and FGF-23 levels.

Step 2 — FGF-23 rises first. Fibroblast growth factor 23 (FGF-23), a phosphaturic hormone secreted by osteocytes in bone, is now recognized as the earliest biomarker of CKD-MBD, rising even before PTH in CKD stage G2. FGF-23 acts on the kidney (requiring its co-receptor Klotho) to inhibit tubular phosphate reabsorption (phosphaturia) and simultaneously to suppress the enzyme 1α-hydroxylase, which converts 25-OH vitamin D to active 1,25-(OH)2D3 (calcitriol). Klotho expression in the kidney falls progressively with CKD, further blunting FGF-23 signaling and leading to even higher FGF-23 levels in a compensatory spiral. In ESRD, FGF-23 levels may be 1,000-fold above normal.

Step 3 — Active vitamin D synthesis falls. FGF-23 directly inhibits renal 1α-hydroxylase, reducing the conversion of 25-OH-D to calcitriol. Additionally, surviving nephron mass itself is reduced, leaving fewer 1α-hydroxylase-expressing cells even if the enzyme were uninhibited. The combined result is profoundly low calcitriol levels despite adequate (or even elevated) 25-OH-D substrate. This is one of the key pathophysiological distinctions of CKD-related vitamin D deficiency from nutritional vitamin D deficiency: even high-dose cholecalciferol supplementation cannot overcome the blocked conversion step — active vitamin D analogs (calcitriol, paricalcitol) are required.

Step 4 — Intestinal calcium absorption falls. Calcitriol is the principal stimulus for intestinal calcium absorption via TRPV6 channels in duodenal enterocytes. With calcitriol deficient, dietary calcium is poorly absorbed, and serum ionized calcium begins to fall. This hypocalcemia is the direct trigger for parathyroid hormone secretion.

Step 5 — PTH rises. The parathyroid CaSR detects the fall in ionized calcium and increases PTH secretion. Initially this is appropriate and partially effective — PTH mobilizes calcium from bone, increases renal calcium reabsorption (tubular), and stimulates (in the normal kidney) residual 1α-hydroxylase activity. In CKD, however, the renal response to PTH is blunted, and the enzyme is already maximally suppressed by FGF-23.

Step 6 — Hyperphosphatemia compounds the problem. As GFR falls further, even maximal PTH and FGF-23-driven phosphaturia cannot maintain phosphate balance, and serum phosphate rises. Hyperphosphatemia has direct effects on the parathyroid gland — it stimulates PTH gene transcription and secretion independent of calcium. Additionally, hyperphosphatemia blunts the CaSR response, requiring even lower calcium levels to trigger PTH release. Elevated phosphate also complexes with calcium, lowering ionized calcium directly.

Step 7 — Parathyroid gland hyperplasia. Prolonged stimulation leads to diffuse hyperplasia of all four parathyroid glands. Initially this is polyclonal and reversible, but over years, nodular hyperplasia develops — monoclonal outgrowths within the hyperplastic glands that express reduced CaSR and reduced vitamin D receptor (VDR), making them less responsive to both calcium feedback and vitamin D analog therapy. This is the transition toward tertiary disease.

KDIGO Staging of CKD-MBD by GFR

KDIGO 2017 recommends staged monitoring based on GFR category: at G3a-G3b (GFR 30-59), check Ca/P every 6-12 months and PTH every 12 months; at G4 (GFR 15-29), Ca/P every 3-6 months and PTH every 6-12 months; at G5/G5D (dialysis), Ca/P every 1-3 months and PTH every 3-6 months. This reflects the accelerating pace of mineral dysregulation as kidney function declines.

Back to Table of Contents

Other Causes

While CKD and vitamin D deficiency dominate the epidemiology of SHPT, several other conditions produce the same pathophysiological outcome: a sustained hypocalcemic or vitamin D-deficient state that forces the parathyroid glands into prolonged compensatory overdrive.

Vitamin D Deficiency (Non-Renal)

The most common cause of SHPT globally. Vitamin D deficiency may result from inadequate sunlight exposure (institutionalized elderly, high-latitude populations, full-body clothing coverage), inadequate dietary intake, or a combination. When 25-OH-D falls below approximately 20 ng/mL, calcitriol synthesis becomes substrate-limited even though renal 1α-hydroxylase function is intact. Intestinal calcium absorption falls, serum PTH rises reactively, and over time the parathyroid glands undergo diffuse hyperplasia. This form of SHPT is generally mild to moderate, normalizes with vitamin D repletion (cholecalciferol 1,000-4,000 IU/day), and does not require active vitamin D analogs because the conversion machinery is intact.

Malabsorption Syndromes

Conditions impairing fat-soluble vitamin absorption are a significant but under-recognized cause of SHPT:

• Celiac disease — villous atrophy in the proximal small intestine impairs both calcium and fat-soluble vitamin D absorption simultaneously. SHPT often persists even after a gluten-free diet until mucosal healing is complete.
• Crohn's disease — ileal disease impairs bile acid recycling, reducing fat-soluble vitamin absorption; surgical resections compound the deficit.
• Gastric bypass surgery (Roux-en-Y) — bypassing the duodenum and proximal jejunum eliminates the primary site of calcium absorption, even when dietary intake is adequate. Post-bariatric SHPT is common, progressive, and requires long-term supplementation with calcium citrate (better absorbed than carbonate in achlorhydric states) plus high-dose vitamin D.
• Short bowel syndrome — massive small bowel resection severely limits absorptive surface for both calcium and vitamin D.

Osteomalacia and Rickets

Osteomalacia (in adults) and rickets (in children) represent the skeletal manifestation of severe, prolonged vitamin D deficiency or phosphate wasting. The undermineralized osteoid acts as a calcium sink, sequestering calcium from the circulation and driving PTH upward. Treatment addresses both the underlying cause and the SHPT simultaneously. Hereditary forms of rickets (X-linked hypophosphatemic rickets, vitamin D-dependent rickets type I — 1α-hydroxylase deficiency — and type II — VDR mutations) each produce severe SHPT through specific defects in the vitamin D activation or signaling pathway.

Chronic Liver Disease

The liver performs the first hydroxylation step of vitamin D metabolism, converting cholecalciferol to 25-OH-D via CYP2R1. In advanced liver disease (cirrhosis), this step is impaired, and 25-OH-D levels fall even in patients with adequate sun exposure. This relative deficiency is compounded by poor oral intake, fat malabsorption from cholestasis, and reduced albumin (which carries vitamin D metabolites in blood). The result is SHPT of mild-to-moderate severity in most patients with cirrhosis.

Prolonged Malnutrition

Severe protein-calorie malnutrition combined with inadequate calcium and vitamin D intake produces SHPT through substrate deficiency. This is seen in the context of anorexia nervosa, extreme poverty, or prolonged exclusive parenteral nutrition without adequate calcium/vitamin D supplementation. The parathyroid response is intact and appropriate; once nutrition is restored, SHPT resolves.

Back to Table of Contents

Tertiary Hyperparathyroidism

Tertiary hyperparathyroidism represents the endpoint of prolonged, untreated or inadequately treated secondary HPT: the parathyroid glands, after years of hyperplastic growth under constant stimulation, develop regions of autonomous secretion that persist even after the original stimulus is removed. The defining biochemical hallmark is hypercalcemia — PTH is elevated and calcium is now high, not low — which distinguishes tertiary from secondary HPT where calcium is characteristically low or low-normal.

Pathogenesis of Autonomy

Within chronically hyperplastic parathyroid tissue, monoclonal nodules emerge over time. These nodular regions accumulate somatic mutations that parallel those seen in parathyroid adenomas of primary HPT:

• CaSR downregulation — reduced CaSR density on nodular cell surfaces means the cell requires a higher calcium concentration to halt PTH secretion. The set-point for calcium-inhibition of PTH is shifted upward.
• VDR downregulation — reduced vitamin D receptor expression makes nodular cells less responsive to calcitriol or active vitamin D analogs.
• Cyclin D1 overexpression — PRAD1/CCND1 gene rearrangement places cyclin D1 under the PTH promoter, driving cell proliferation.
• MEN1 tumor suppressor loss — somatic mutations in the MEN1 gene (menin) are found in a subset of nodular hyperplasia cells, identical to the germline mutation causing hereditary MEN1 syndrome.

Tertiary HPT After Renal Transplantation

The most common clinical setting for tertiary HPT is the post-renal transplant patient. Approximately 10-30% of successful kidney transplant recipients develop hypercalcemia within the first year after transplantation. The mechanism is straightforward: years of CKD-driven parathyroid hyperplasia left massively enlarged glands with autonomous nodular secretion. When the new kidney restores normal phosphate clearance and resumes 1α-hydroxylase activity, the previously deficient calcium environment is suddenly corrected — but the autonomous glands keep secreting PTH regardless. The resulting hypercalcemia causes graft dysfunction (PTH-driven nephrocalcinosis, nephrolithiasis in the transplanted kidney), impaired graft survival, bone loss, and cardiovascular risk.

In most post-transplant patients, hyperparathyroidism resolves spontaneously within 12 months as the enlarged glands gradually involute. Persistent hypercalcemia beyond 12-24 months, or severe hypercalcemia impairing graft function, requires either cinacalcet therapy or parathyroidectomy.

Distinguishing Tertiary from Primary HPT

Both present with high PTH and high calcium. The clinical history is the critical differentiator: tertiary HPT occurs in a patient with a known history of CKD, dialysis, or renal transplantation, often with documented prior hypocalcemia and years of elevated PTH. Primary HPT typically arises de novo without prior renal disease. Parathyroid gland size on imaging also differs: tertiary HPT typically shows uniformly enlarged, multiglandular disease (four-gland hyperplasia or multiple nodular glands), while primary HPT more commonly shows a single adenoma, though multiglandular disease occurs in primary HPT as well (especially in MEN1).

Back to Table of Contents

Clinical Presentation and Complications

The clinical picture of SHPT depends heavily on its underlying cause and duration. Mild SHPT from nutritional vitamin D deficiency may be entirely asymptomatic, discovered incidentally on laboratory testing. Severe, long-standing CKD-SHPT produces a constellation of skeletal, vascular, cardiac, and dermatological complications that together constitute a major cause of morbidity and mortality in dialysis patients.

Renal Osteodystrophy

Renal osteodystrophy is the umbrella term for the bone disease of CKD, classified by bone histology on tetracycline-labeled bone biopsy:

• High-turnover disease (osteitis fibrosa cystica) — excess PTH drives osteoclast and osteoblast activity disproportionately, with increased cortical porosity, trabecular thinning, and replacement of marrow space by fibrous tissue. Classic radiographic findings include subperiosteal bone resorption at the radial aspect of the middle phalanges, "salt-and-pepper" skull, and (in severe cases) the rare brown tumor — a lytic lesion filled with fibrovascular tissue mimicking giant-cell tumor. Patients present with bone pain, fractures, and skeletal deformity.
• Low-turnover disease (adynamic bone disease) — paradoxically, overly aggressive suppression of PTH with active vitamin D or calcimimetics can produce the opposite problem: too little bone turnover, leaving bone unable to repair microfractures and paradoxically brittle. Adynamic bone disease is increasingly common in dialysis patients who are over-treated or who have diabetes (which independently suppresses bone turnover).
• Osteomalacia — deficient mineralization of osteoid; in the modern era usually due to aluminum toxicity (historic, from aluminum-containing phosphate binders) or severe vitamin D deficiency.
• Mixed uremic osteodystrophy — combinations of the above, most commonly high-turnover superimposed on osteomalacia.

Vascular Calcification

Vascular calcification in CKD-SHPT is predominantly medial — calcium-phosphate crystals deposit in the tunica media of muscular arteries, causing arterial stiffening, reduced vascular compliance, and increased pulse pressure. This is mechanistically distinct from the intimal, plaque-based atherosclerotic calcification of coronary artery disease, though both coexist in CKD patients. Medial calcification is driven by hyperphosphatemia, elevated calcium-phosphate product, and loss of vascular calcification inhibitors (fetuin-A, matrix Gla protein — both vitamin K-dependent). The stiff, calcified arteries impair cardiac afterload reduction, contributing to left ventricular hypertrophy (LVH) and diastolic dysfunction, and increase the risk of myocardial infarction and stroke.

Calciphylaxis

Calciphylaxis — also called calcific uremic arteriolopathy (CUA) — is one of the most devastating complications of CKD-SHPT. Calcium-phosphate crystals deposit in the walls of small dermal arterioles, triggering intimal hyperplasia, thrombosis, and occlusion of the microcirculation. The result is ischemic necrosis of skin and subcutaneous fat, presenting as:

• Intensely painful, indurated livedo reticularis or stellate purpura
• Rapidly evolving skin necrosis with eschar formation, often at the flanks, thighs, abdomen, or buttocks (high-fat areas with poor perfusion)
• Superinfected wounds that become portals for sepsis

Calciphylaxis carries an estimated 1-year mortality of 45-80%, with sepsis from infected wounds as the leading cause of death. Risk factors include female sex, obesity, diabetes, warfarin use (warfarin inhibits matrix Gla protein carboxylation, removing a critical anti-calcification defense), elevated calcium-phosphate product, and high-dose calcium-containing phosphate binders. Treatment centers on sodium thiosulfate (25 g IV three times per week after dialysis — chelates calcium, improves endothelial function, and has antioxidant effects), meticulous wound care, pain management, and normalization of the calcium-phosphate product. Parathyroidectomy is sometimes performed for refractory cases, though evidence is limited.

Cardiovascular Complications

PTH itself has direct adverse cardiovascular effects beyond its mineral regulatory role. PTH receptors are expressed in cardiac myocytes, vascular smooth muscle, and endothelial cells. Chronically elevated PTH promotes left ventricular hypertrophy (LVH), myocardial fibrosis, and cardiomyopathy. Epidemiological studies in CKD patients consistently show elevated PTH as an independent predictor of cardiovascular events and all-cause mortality, even after adjustment for traditional cardiovascular risk factors. Calcification of cardiac valves (aortic and mitral) is also more common in CKD-SHPT, contributing to valvular heart disease.

Vitamin D Deficiency Symptoms

When SHPT is driven by nutritional vitamin D deficiency rather than CKD, the clinical picture is dominated by the manifestations of low calcitriol and consequent hypocalcemia: generalized fatigue and malaise, diffuse bone pain (especially axial skeleton), proximal muscle weakness (myopathy — difficulty rising from a chair or climbing stairs), depression and cognitive difficulties, and impaired immune function. These are the symptoms that respond most dramatically to vitamin D repletion.

Back to Table of Contents

Diagnosis and Laboratory Evaluation

The diagnosis of SHPT is established biochemically. The essential distinction from primary HPT — and the guide to identifying the underlying cause — lies in the calcium level: in secondary HPT, calcium is low or low-normal; in primary HPT, calcium is high. Both have elevated PTH.

Core Laboratory Panel

• Serum calcium (total and ionized) — total calcium must be albumin-corrected (add 0.8 mg/dL for every 1 g/dL albumin falls below 4.0); ionized calcium is the physiologically relevant fraction. Low or low-normal in SHPT; elevated in primary HPT and tertiary HPT.
• Serum phosphorus — low in primary HPT (PTH drives phosphaturia); elevated in CKD-SHPT (impaired renal excretion overwhelming PTH-driven phosphaturia); may be low-normal in nutritional vitamin D deficiency SHPT. Target in CKD: 3.5-5.5 mg/dL.
• Intact PTH (iPTH) — elevated in all forms of HPT. In CKD-SHPT, target levels vary by stage: KDIGO 2017 recommends maintaining PTH within approximately 2-9 times the upper limit of normal for the assay, acknowledging that PTH bioactivity is altered in uremia and some PTH fragments detected by intact assays are biologically inactive.
• 25-OH vitamin D — the best measure of vitamin D stores. Deficiency (<20 ng/mL) or insufficiency (20-30 ng/mL) is the most common treatable cause of SHPT. In CKD, low 25-OH-D may be treated with cholecalciferol, but 1,25-(OH)2D3 (calcitriol) measurement is needed to assess active vitamin D status separately.
• 1,25-(OH)2D3 (calcitriol) — often low in CKD-SHPT even when 25-OH-D is adequate, because 1α-hydroxylase is suppressed by FGF-23 and nephron loss. Low calcitriol with normal 25-OH-D in CKD is expected and indicates need for active vitamin D analogs rather than more cholecalciferol.
• FGF-23 — emerging biomarker of early CKD-MBD and cardiovascular risk; rises before PTH in CKD; not yet standard clinical practice but increasingly measured in research and advanced CKD management.
• Alkaline phosphatase (ALP), bone-specific ALP — elevated in high-turnover renal osteodystrophy (osteitis fibrosa); may be normal or low in adynamic bone disease.
• Calcium × phosphate product (Ca × P) — target <55 mg²/dL² in dialysis patients (some guidelines use mmol²/L² equivalent); above this threshold, calcium-phosphate precipitation and vascular calcification risk rise sharply.

Distinguishing Primary from Secondary HPT

The critical differential is captured in a simple 2×2: in primary HPT, calcium is HIGH and PTH is inappropriately high (both should not be simultaneously elevated in a normal feedback system). In secondary HPT, calcium is LOW (or low-normal) and PTH is HIGH (appropriate response). In tertiary HPT, calcium is HIGH and PTH is HIGH — indistinguishable from primary HPT biochemically, but the history of CKD/dialysis/transplant identifies it.

Imaging Studies

• Bone densitometry (DXA) — assesses cortical and trabecular bone density; useful for monitoring treatment response.
• Plain radiography — subperiosteal bone resorption at the radial aspect of the middle phalanges is pathognomonic of osteitis fibrosa from hyperparathyroidism. Rarely seen in well-managed modern CKD but may appear in undiagnosed cases.
• Tc-99m sestamibi parathyroid scan + neck ultrasound — used to localize enlarged parathyroid glands before parathyroidectomy; most useful when tertiary HPT or multiglandular disease requires surgical planning. Not needed for the diagnosis of SHPT itself, which is biochemical.
• Bone biopsy with tetracycline labeling — the gold standard for classifying renal osteodystrophy subtype (high-turnover vs. adynamic vs. mixed vs. osteomalacia); rarely performed because it is invasive, but important when the clinical picture is ambiguous or when aluminum toxicity is suspected.

Back to Table of Contents

Treatment

Treatment of SHPT is directed at the underlying cause, the specific stage of CKD, and the biochemical targets established by KDIGO 2017 guidelines. The approach differs substantially between nutritional SHPT and CKD-SHPT.

Treating Vitamin D Deficiency SHPT

For SHPT driven by nutritional vitamin D deficiency (without significant CKD), treatment is straightforward:

• Cholecalciferol (vitamin D3) — 1,000-4,000 IU per day orally for maintenance; loading doses of 50,000 IU weekly for 8-12 weeks (prescription ergocalciferol or high-dose D3) for moderate-to-severe deficiency. The goal is to raise 25-OH-D above 30 ng/mL, which normalizes calcitriol synthesis and restores calcium absorption. PTH typically normalizes within 3-6 months of adequate repletion.
• Calcium supplementation — if dietary calcium intake is inadequate, calcium citrate 500-1,000 mg elemental calcium per day with meals. Calcium carbonate requires gastric acid for absorption and is less suitable for patients on proton pump inhibitors or post-gastric bypass.
• Treatment of malabsorption — addressing the underlying cause (gluten-free diet for celiac, bowel rest and anti-inflammatory treatment for Crohn's, specific supplementation protocols for post-bariatric patients) is essential; vitamin D supplementation alone may be insufficient without mucosal healing.

CKD-SHPT: Phosphate Control

Phosphate control is foundational to CKD-MBD management — it is the root event in the cascade and independently drives PTH secretion and vascular calcification.

• Dietary phosphate restriction — limiting processed foods with phosphate additives (inorganic phosphate is nearly 100% absorbed vs. 60% for organic food phosphate); protein restriction in advanced CKD (also reduces phosphate intake but must be balanced against protein-energy malnutrition risk).
• Calcium-based phosphate binders — calcium carbonate and calcium acetate bind dietary phosphate in the gut, preventing absorption. Inexpensive and effective, but calcium loading can worsen vascular calcification — calcium-based binders should be used cautiously in patients with existing calcification, hypercalcemia, or adynamic bone disease.
• Non-calcium phosphate binders (preferred) — sevelamer carbonate (polymer that also reduces LDL cholesterol and absorbs uremic toxins) and lanthanum carbonate are the preferred binders when calcium loading is a concern. Ferric citrate has the added benefit of treating iron deficiency anemia. These agents avoid the calcium loading of carbonate/acetate.

Active Vitamin D Analogs

Because renal 1α-hydroxylase is suppressed in CKD, native vitamin D supplementation is insufficient for suppressing PTH in CKD-SHPT — pre-activated analogs are required:

• Calcitriol (1,25-(OH)2D3) — the bioactive form of vitamin D; oral 0.25 mcg/day, titrated upward. Suppresses PTH transcription via VDR in parathyroid cells. Risk: hypercalcemia and hyperphosphatemia with overdose, requiring close monitoring.
• Paricalcitol (19-nor-1,25-(OH)2D2) — selective VDR activator with less calcemic and phosphatemic effect than calcitriol; preferred by many nephrologists for the reduced hypercalcemia/hyperphosphatemia risk.
• Doxercalciferol (1α-OH-D2) — requires hepatic activation; intermediate calcemic activity.

Calcimimetics

Cinacalcet (Sensipar) is a calcimimetic agent that allosterically sensitizes the CaSR on parathyroid chief cells — it makes the CaSR behave as though calcium is higher than it actually is, powerfully suppressing PTH secretion without raising serum calcium or phosphorus. This is its key advantage over active vitamin D analogs, which suppress PTH but also raise calcium and phosphorus.

• Dosing: 30 mg/day initially, titrated to 60-90-120-180 mg/day based on PTH and calcium response.
• FDA approved for secondary HPT in adults on dialysis (CKD G5D); approved for hypercalcemia in parathyroid carcinoma and primary HPT (calcimimetics are not approved for CKD G3-G4 non-dialysis — the EVOLVE and ADVANCE trials showed mortality signals in non-dialysis CKD).
• Main side effects: nausea, vomiting (significant cause of discontinuation), hypocalcemia (cinacalcet lowers PTH which reduces calcium; calcium must be monitored closely).
• Etelcalcetide (Parsabiv) — an IV calcimimetic administered at dialysis, avoiding the oral absorption issues of cinacalcet; approved for dialysis patients with SHPT.

Dialysis Optimization

Dialysis modality and prescription affect mineral control: high-flux hemodialysis clears phosphate more effectively than low-flux; longer or more frequent dialysis sessions (nocturnal dialysis 6 nights/week, or daily short-session dialysis) significantly reduce phosphate burden and allow relaxation of dietary restrictions and phosphate binder loads. Dialysate calcium concentration (typically 2.5 mEq/L) is titrated to avoid hypercalcemia while maintaining positive calcium balance.

Parathyroidectomy

Surgical removal of the parathyroid glands is reserved for severe, refractory SHPT that fails medical management. KDIGO 2017 surgical indications include: persistently very high PTH (>800 pg/mL, equivalent to approximately 9 times the upper limit of normal) despite optimized medical therapy; symptomatic hypercalcemia refractory to cinacalcet; progressive renal osteodystrophy; calciphylaxis; or planned renal transplantation in a patient with massive parathyroid hyperplasia.

Surgical options:

• Subtotal parathyroidectomy — removal of 3.5 glands, leaving a remnant of approximately 50-60 mg in situ; advantages: avoids neck re-exploration if recurrence occurs; disadvantages: risk of recurrence if remnant undergoes further autonomous hyperplasia.
• Total parathyroidectomy with autotransplantation — all four glands removed; a portion (~50-60 mg) is transplanted into the brachioradialis muscle of the non-dominant forearm; if hyperparathyroidism recurs, the forearm mass can be partially excised under local anesthesia without neck re-exploration.

Post-parathyroidectomy hypocalcemia ("hungry bone syndrome") is the major early complication — the skeleton, starved of calcium for years under high PTH, avidly takes up calcium from the circulation once PTH falls, causing severe, symptomatic hypocalcemia within hours of surgery. Prophylactic calcitriol plus high-dose calcium supplementation (oral and IV) must be started perioperatively and tapered slowly over weeks to months.

Back to Table of Contents

Prognosis and Monitoring

The prognosis of SHPT is tightly linked to its underlying cause and the adequacy of management. Nutritional vitamin D deficiency-driven SHPT is highly treatable and carries an excellent prognosis when corrected. CKD-SHPT, however, is a marker of advanced renal disease and contributes independently to the dramatically elevated cardiovascular mortality of dialysis patients — whose annual cardiovascular mortality is 10-20 times higher than age-matched general population controls.

KDIGO Monitoring Intervals

For CKD patients not on dialysis, KDIGO 2017 recommends monitoring frequency based on GFR category and trajectory:

• CKD G3a-G3b: calcium and phosphorus every 6-12 months; PTH every 12 months; 25-OH-D at baseline, then as clinically indicated.
• CKD G4: calcium and phosphorus every 3-6 months; PTH every 6-12 months.
• CKD G5/G5D (including dialysis): calcium and phosphorus every 1-3 months; PTH every 3-6 months. More frequent monitoring (monthly) is appropriate during active dose titration of binders, calcitriol, or cinacalcet.

Treatment Targets

• Calcium: maintain within the normal range for the assay; avoid hypercalcemia (Ca >10.2 mg/dL corrected). KDIGO recommends avoiding hypercalcemia in CKD G3-G5D.
• Phosphorus: KDIGO 2017 recommends lowering elevated phosphorus levels toward the normal range in CKD G3a-G5D (3.5-5.5 mg/dL). Ca × P product target: <55 mg²/dL².
• PTH: for CKD G3a-G5 not on dialysis, maintain within the normal range (10-65 pg/mL). For CKD G5D (dialysis), KDIGO recommends maintaining iPTH within approximately 2-9 times the upper normal limit (roughly 130-600 pg/mL with a typical ULN of 65 pg/mL), accepting some degree of elevation because PTH action is blunted in uremia and suppressing PTH to normal leads to adynamic bone disease. The optimal PTH target remains a subject of ongoing debate in nephrology.

Progression to Tertiary HPT

The risk of tertiary hyperparathyroidism correlates with the duration and severity of SHPT, the degree of parathyroid gland enlargement (glands >500 mg or >1 cm on imaging are at high risk for nodular hyperplasia), and inadequacy of treatment. Early and aggressive phosphate control, early introduction of active vitamin D analogs, and monitoring for progressive PTH elevation are the primary prevention strategy. Once nodular hyperplasia is established, medical therapy becomes less effective and parathyroidectomy may be the only durable solution.

Calciphylaxis Prognosis

Calciphylaxis carries a 1-year mortality of approximately 45-80% in most series, driven predominantly by sepsis from infected wounds and cardiovascular complications. Nonulcerating lesions carry a somewhat better prognosis than ulcerating lesions. Sodium thiosulfate has emerged as the most evidence-supported treatment, with several retrospective series showing improved healing and survival, though no randomized controlled trial has been completed. Aggressive wound care, optimization of dialysis, normalization of the Ca × P product, conversion from calcium-based to non-calcium phosphate binders, and cessation of warfarin (where anticoagulation permits) are all critical components of management.

FGF-23 as an Emerging Biomarker

FGF-23 is emerging as an important cardiovascular risk biomarker in CKD independent of traditional risk factors. Prospective studies have demonstrated that elevated FGF-23 predicts mortality, LVH, and progression to ESRD, and that FGF-23 levels in early CKD (G2-G3) already carry prognostic information even before PTH rises. Whether FGF-23-lowering interventions improve outcomes (beyond the benefits of phosphate reduction) is an active area of research. The SELECT-FGF-23 trial and related studies are exploring this question. For now, FGF-23 is primarily a research tool and prognostic biomarker rather than a clinical treatment target, but its place in CKD-MBD monitoring is likely to expand.

Post-Transplant Course

After successful renal transplantation, serum phosphorus often drops precipitously (transplant-associated hypophosphatemia from persistent FGF-23 elevation plus functional tubular phosphate wasting) while calcium tends to rise. PTH falls progressively over 12-24 months as the newly functioning kidney restores vitamin D activation and phosphate clearance, and as the parathyroid glands gradually involute. Most patients with pre-transplant SHPT do not require parathyroidectomy; cinacalcet can bridge the post-transplant period for patients with persistent hypercalcemia or markedly elevated PTH. Those who do require surgery typically have glands >1 cm with nodular hyperplasia and PTH that fails to downtrend over the first year.

Back to Table of Contents

Key Research Papers

Landmark Studies

1. Ketteler M, et al. Diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder: summary of KDIGO 2017 Clinical Practice Guideline update. Kidney Int 2017. PMID 28657815
2. Block GA, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004. PMID 20089977
3. Goodman WG, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000. PMID 11566527
4. Isakova T, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011. PMID 21071527
5. Shigematsu T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004. PMID 17699274
6. Ketteler M, et al. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD. Kidney Int Suppl 2017. PMID 29343516
7. Tentori F, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008. PMID 18558473
8. Cannata-Andia JB, et al. Vascular calcification and calcium phosphate imbalance. Am J Kidney Dis 2006. PMID 16239581
9. Nigwekar SU, et al. Calciphylaxis. N Engl J Med 2018. PMID 23258226
10. Rodriguez M, et al. New treatments for secondary hyperparathyroidism. J Am Soc Nephrol 2009. PMID 19620205
11. Locatelli F, et al. Vitamin D receptor activators and clinical outcomes in chronic kidney disease. Kidney Int 2006. PMID 16988585
12. Kalantar-Zadeh K, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2010. PMID 20864939

PubMed Topic Searches

1. Secondary hyperparathyroidism CKD treatment
2. FGF-23 chronic kidney disease mineral metabolism
3. Calciphylaxis sodium thiosulfate treatment
4. Cinacalcet secondary hyperparathyroidism dialysis
5. Renal osteodystrophy bone biopsy CKD
6. Vitamin D deficiency secondary hyperparathyroidism

Back to Table of Contents

Connections

• Hyperparathyroidism — general overview of all hyperparathyroidism types, including primary and secondary
• Primary Hyperparathyroidism — autonomous PTH excess causing hypercalcemia; contrast with the reactive hypocalcemic pattern of secondary HPT
• Hypoparathyroidism — insufficient PTH secretion; the opposite end of the parathyroid spectrum from secondary HPT
• Chronic Kidney Disease — CKD is the dominant cause of severe secondary hyperparathyroidism and drives the CKD-MBD cascade
• Vitamin D3 — vitamin D deficiency is the most common cause of secondary HPT worldwide; active vitamin D analogs are the cornerstone of CKD-SHPT treatment
• Calcium — calcium physiology and the calcium-sensing receptor axis are central to parathyroid regulation and SHPT pathogenesis
• Phosphorus — phosphate retention in CKD drives FGF-23 elevation, suppresses vitamin D synthesis, and directly stimulates PTH secretion
• Endocrinology Conditions — full index of endocrine disorders covered on this site

Back to Table of Contents

Featured Videos